Target Name: KLRF1
NCBI ID: G51348
Review Report on KLRF1 Target / Biomarker Content of Review Report on KLRF1 Target / Biomarker
KLRF1
Other Name(s): Lectin-like receptor F1 | Killer cell lectin like receptor F1, transcript variant 1 | activating coreceptor NKp80 | KLRF1_HUMAN | C-type lectin domain family 5 member C | Activating coreceptor NKp80 | lectin-like receptor F1 | Killer cell lectin-like receptor subfamily F member 1 | Killer cell lectin-like receptor subfamily F member 1 (isoform 1) | killer cell lectin like receptor F1 | CLEC5C | MGC119909 | KLRF1 variant 1 | MGC119908 | NKp80 | MGC119907 | Killer cell lectin-like receptor F1 | ML | killer cell lectin-like receptor subfamily F, member 1

KLRF1: A Protein Involved in Multiple Biological Processes

KLRF1 (Lectin-like receptor F1) is a protein that is expressed in various tissues throughout the body, including the skin, hair, nails, and eyes. It is a member of the Lectin-like receptor family, which includes proteins that are involved in the process of cell-cell adhesion and the regulation of inflammation. KLRF1 has been shown to play a role in several important biological processes, including tissue repair, wound healing, and inflammation.

Disease and Treatment

KLRF1 has been linked to several diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these diseases has led to the development of new therapeutic approaches. For example, KLRF1 has been shown to be involved in the development of cancer, and researchers have identified several potential drug targets that can be targeted to treat these diseases.

One potential drug target for KLRF1 is the inhibition of its activity, as has been shown to have therapeutic effects in several studies. For example, researchers have found that inhibiting the activity of KLRF1 can significantly reduce the growth of cancer cells. This is because KLRF1 plays a role in the regulation of cell growth and division, and inhibiting its activity can lead to the inhibition of these processes.

Another potential drug target for KLRF1 is the regulation of inflammation. KLRF1 has been shown to be involved in the regulation of inflammation, and researchers have identified several potential drug targets that can be targeted to treat inflammatory disorders. For example, KLRF1 has been shown to play a role in the regulation of pain, and inhibiting its activity can lead to the relief of pain.

KLRF1 has also been shown to be involved in the regulation of tissue repair and regeneration. This is an important process that is involved in the repair of damaged tissue and the regeneration of new tissue in the body. KLRF1 has been shown to play a role in this process, and inhibiting its activity can lead to the inhibition of tissue repair and regeneration.

Conclusion

In conclusion, KLRF1 is a protein that is involved in several important biological processes in the body. Its role in these processes has led to the development of several potential drug targets, including the inhibition of its activity in the regulation of cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of KLRF1 in these processes and to develop effective treatments for these diseases.

Protein Name: Killer Cell Lectin Like Receptor F1

Functions: Involved in the natural killer (NK)-mediated cytolysis of PHA-induced lymphoblasts

The "KLRF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLRF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

KLRF2 | KLRG1 | KLRG2 | KLRK1 | KLRK1-AS1 | KMO | KMT2A | KMT2B | KMT2C | KMT2CP4 | KMT2D | KMT2E | KMT2E-AS1 | KMT5A | KMT5B | KMT5C | KNCN | KNDC1 | KNG1 | KNL1 | KNOP1 | KNOP1P5 | KNSTRN | KNTC1 | KPNA1 | KPNA2 | KPNA3 | KPNA4 | KPNA5 | KPNA6 | KPNA7 | KPNB1 | KPNB1-DT | KPRP | KPTN | KRAS | KRASP1 | KRBA1 | KRBA2 | KRBOX1 | KRBOX1-AS1 | KRBOX4 | KRBOX5 | KRCC1 | KREMEN1 | KREMEN2 | KRI1 | KRIT1 | KRR1 | KRT1 | KRT10 | KRT10-AS1 | KRT12 | KRT126P | KRT13 | KRT14 | KRT15 | KRT16 | KRT16P1 | KRT16P2 | KRT16P3 | KRT16P6 | KRT17 | KRT17P1 | KRT17P2 | KRT17P3 | KRT17P5 | KRT17P7 | KRT18 | KRT18P1 | KRT18P12 | KRT18P13 | KRT18P16 | KRT18P17 | KRT18P19 | KRT18P22 | KRT18P23 | KRT18P24 | KRT18P27 | KRT18P28 | KRT18P29 | KRT18P31 | KRT18P33 | KRT18P34 | KRT18P4 | KRT18P40 | KRT18P41 | KRT18P42 | KRT18P44 | KRT18P48 | KRT18P49 | KRT18P5 | KRT18P50 | KRT18P51 | KRT18P55 | KRT18P59 | KRT18P6 | KRT18P62 | KRT19 | KRT19P2